ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 387-392

  Oprea Lager, Daniela E ^a   Bijnsdorp, Irene V ^a   Van Moorselaar, Reindert J A ^a   Van Den Eertwegh, Alfons J M ^b   Hoekstra, Otto S ^a   Geldof, Albert A ^a,b  

^a Department of Radiology and Nuclear Medicine ^*  (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABCC4; Cabazitaxel; Docetaxel resistance.; Prostate cancer cell lines

Indexed keywords

ATP CASSETTE BINDING PROTEIN 4; CABAZITAXEL; DOCETAXEL; MEMBRANE PROTEIN; SULFORHODAMINE B; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84875907779     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der KT, Wiegel T and Zattoni F: EAU guidelines on prostate cancer. Part I: Screening, diagnosis, and treatment of clinically localised disease. Actas Eur Urol 59(1): 61-71, 2011.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
4. Michielsen DP, Braeckman JG and Denis L: Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother 12: 977-982, 2011.
5. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S and Sartor AO: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376: 1147-1154, 2010.
7. Paller CJ and Antonarakis ES: Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 5: 117-124, 2011.
8. Parente P, Parnis F and Gurney H: Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective. Asia-Pac J Clin Oncol 8: 31-42, 2012.
9. Higano CS and Crawford ED: New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol 29(6 Suppl): S1-S8, 2011.
10. Cai C, Omwancha J, Hsieh CL and Shemshedini L: Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis 10: 39-45, 2007.
11. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD and Horvath LG: Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 68: 1421-1429, 2008.
12. Geldof AA, Rao BR and De Voogt HJ: Direct effects of chemotherapeutic agents on rat prostate tumor clonogenic cells. Anticancer Res 6: 837-840, 1986.
13. Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M and Peters GJ: Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 99: 2302-2308, 2008.
14. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M and Kruyt FA: Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 126: 2457-2468, 2010.
15. Chen ZS and Tiwari AK: Multidrug-resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278: 3226-3245, 2011.
16. Diestra JE, Condom E, Del M, X, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, Germa-Lluch JR and Izquierdo MA: Expression of multidrug resistance proteins P-glycoprotein, multidrug-resistance protein 1, breast cancer-resistance protein and lung-resistance-related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: Biological and clinical implications. J Urol 170: 1383-1387, 2003.
17. Sanchez C, Mercado A, Contreras HR, Mendoza P, Cabezas J, Acevedo C, Huidobro C and Castellon EA: Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock-down of multidrug-resistance proteins. Prostate 71: 1810-1817, 2011.
18. Van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G and Scheper RJ: ABC drug transporters and immunity: Novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 86: 1075-1087, 2009.
19. Rius M, Thon WF, Keppler D and Nies AT: Prostanoid transport by multidrug-resistance protein 4 (MRP4/ABCC4) localized in tissues of the human urogenital tract. J Urol 174: 2409-2414, 2005.
20. Sartor O: Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 4: 18-25, 2011.